Kolon Life Science Inc (102940) — Cash Flow-to-Debt Ratio
Kolon Life Science Inc (102940) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of ₩2.58 Billion could theoretically repay 0% of its total liabilities (₩295.72 Billion) in one year. See 102940 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kolon Life Science Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Kolon Life Science Inc across 11 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Kolon Life Science Inc.
Annual Cash Flow-to-Debt Ratio for Kolon Life Science Inc (2014–2024)
Year-by-year debt coverage analysis for Kolon Life Science Inc. Check Kolon Life Science Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.05x | ₩-14.08 Billion | ₩270.23 Billion | ▲ +64.0% |
| 2023 | -0.14x | ₩-24.87 Billion | ₩171.76 Billion | ▼ -1.6% |
| 2022 | -0.14x | ₩-20.85 Billion | ₩146.39 Billion | ▼ -19.0% |
| 2021 | -0.12x | ₩-16.19 Billion | ₩135.25 Billion | ▼ -211.8% |
| 2020 | -0.04x | ₩-7.31 Billion | ₩190.38 Billion | ▲ +66.3% |
| 2019 | -0.11x | ₩-20.18 Billion | ₩177.27 Billion | ▼ -44.6% |
| 2018 | -0.08x | ₩-13.60 Billion | ₩172.76 Billion | ▼ -62.7% |
| 2017 | -0.05x | ₩-8.29 Billion | ₩171.38 Billion | ▼ -116.3% |
| 2016 | 0.30x | ₩28.11 Billion | ₩94.78 Billion | ▲ +32.8% |
| 2015 | 0.22x | ₩20.81 Billion | ₩93.17 Billion | ▲ +34.3% |
| 2014 | 0.17x | ₩12.10 Billion | ₩72.72 Billion | — |